PeppiLibrary

Cognitive

Selank peptide reference

Russian-developed anxiolytic peptide. Typically administered intranasally.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Selank notes
Default dose label300 mcg
Preferred routeIntranasal
Frequency label1–3× daily as needed
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Clinical use in Russia since 2009; multiple Russian-language clinical trials

Prescription medication in Russia; research chemical elsewhere

Route map

How records are usually labeled

1 Intranasal
2 SubQ

Alternate nostrils with each dose to avoid local irritation.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; powder is stable frozen.
After mixRefrigerate 2–8 °C; nasal spray bottles use within 14–30 days due to repeated bottle access.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 300 mcg
Route Intranasal
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Selank. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Selank is a synthetic heptapeptide analog of tuftsin developed at the Russian Academy of Sciences' Institute of Molecular Genetics. It has been researched for anxiolytic effects, cognitive enhancement, and immunomodulation. Approved as a prescription anxiolytic in Russia; sold as research-only in most other countries. Typically administered as a nasal spray for rapid CNS uptake.

Also known as: TP-7 analog, Tuftsin analog.

Acute anxiety reductionCognitive support under stressMood modulation (clinical research)

Mechanism and timing snapshot

Modulates GABAergic and serotonergic systems; upregulates BDNF and enkephalin expression; immunomodulatory effects via tuftsin-like activity.

Onset label5 min
Catalog onset field, when available.
Half-life label6 min
Plasma half-life ~5–15 min, but downstream effects (BDNF, mood) persist hours
Duration label4 hr
Catalog duration field, when available.
intranasal Moderate to high (rapid CNS uptake via olfactory route)
subQ High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose300 mcg
Catalog dose range250 mcg - 900 mcg
Default routeIntranasal
Frequency label1–3× daily as needed
Best time labelAs needed during high-stress windows; not typically dosed late evening.
Food noteNone.

Catalog protocol note

250–500 mcg intranasal 1–3× daily for 10–14 days.

Routes and site notes

Available route labelsIntranasal, SubQ
Preferred route labelIntranasal
Common site labelsBoth nostrils, alternating
Site rotation noteAlternate nostrils with each dose to avoid local irritation.

Chemistry

SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro
Amino acids7
Molecular formulaC33H57N11O9
Molecular weight751.87 Da

Vial, reconstitution, and storage

Supply formLyophilized powder or pre-formulated nasal spray
Typical vial size5 mg
DiluentBacteriostatic water (or saline for nasal use)
Diluent volume5 mL
Concentration note5 mg in 5 mL → 0.30 mL = 300 mcg per spray (depends on sprayer calibration).
Before reconstitutionRefrigerate 2–8 °C; powder is stable frozen.
After reconstitutionRefrigerate 2–8 °C; nasal spray bottles use within 14–30 days due to repeated bottle access.
Reconstituted shelf life30 days
Light sensitiveNo
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Mild nasal dryness or irritation (intranasal)
  • Transient headache early in use
  • Drowsiness
  • Lightheadedness

Contraindications and warnings

  • Pregnancy
  • Severe psychiatric disorders without clinician oversight
  • Approved as a prescription drug only in Russia; research-only elsewhere.

Other considerations

  • Onset is rapid (~minutes) — useful for acute anxiety windows.
  • Generally well-tolerated in published clinical use.

Evidence and regulatory context

Evidence levelClinical use in Russia since 2009; multiple Russian-language clinical trials
FDA approvedNo
Regulatory statusPrescription medication in Russia; research chemical elsewhere
Prescription requiredYes
Approved countriesRussia

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteBenzodiazepines without clinician oversight
Typical cycle label1–2
Typical break label1–2
Cycle guidanceShort courses (10–14 days) with breaks; continuous long-term use is less studied.

Tracking tips

  • Best as a targeted tool during acute stress, not a daily 'maintenance' supplement.
  • Alternate nostrils to prevent localised irritation.
  • Effects are noticeable but subtle — not sedating like a benzodiazepine.

References

Track it in Peppi

Keep Selank records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Selank?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Selank?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Selank records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026